Does Sermorelin Cause Dizziness?
Based on FDA drug labeling data, sermorelin does cause dizziness as a documented adverse effect, occurring in 12% of patients in clinical trials—significantly higher than the 8% placebo rate. 1
Evidence from FDA Drug Labeling
The most reliable evidence comes from the FDA-approved drug label for sermorelin, which explicitly lists dizziness as a common adverse reaction occurring in 12% of treated patients versus 8% in placebo-treated patients 1. This represents a clinically meaningful 50% relative increase over placebo rates.
Key Clinical Details:
- Incidence: 12% of patients (versus 8% placebo)
- Classification: Listed among nervous system disorders in the adverse reaction profile
- Context: Dizziness was common enough to be included in the primary adverse reaction table alongside other frequent side effects like nausea (26%), diarrhea (20%), and somnolence (11%)
Additional Adverse Effects to Monitor
Beyond dizziness, sermorelin's FDA label documents several other nervous system effects that may co-occur:
- Somnolence (11% vs 6% placebo)
- Tremor (9% vs 2% placebo)
- Fatigue (12% vs 8% placebo)
- Headache (common enough to cause discontinuation in some patients)
These effects suggest sermorelin has meaningful central nervous system activity that can impair alertness and coordination.
Clinical Implications
Patients should be counseled about:
- The 1-in-8 likelihood of experiencing dizziness
- Avoiding activities requiring alertness (driving, operating machinery) until individual response is known
- The potential for additive effects if combined with other CNS-active medications
- That dizziness may be dose-related and could improve with dose adjustment
Important caveat: The research literature on sermorelin 2, 3, 4 focuses primarily on growth hormone stimulation and growth promotion in children, with limited systematic reporting of adverse effects. The most comprehensive safety data comes from the FDA drug label based on controlled trials 1.
Practical Monitoring Approach
When prescribing sermorelin:
- Baseline assessment: Document any pre-existing dizziness or balance issues
- Initial dosing: Start at recommended doses and monitor for first 24-48 hours when dizziness is most likely to manifest
- Ongoing surveillance: Ask specifically about dizziness at each follow-up, as patients may not spontaneously report it
- Dose adjustment: If dizziness is problematic, consider dose reduction before discontinuation
The evidence is clear and consistent: dizziness is a documented, relatively common adverse effect of sermorelin that warrants patient counseling and clinical monitoring.